Strongbridge Biopharma plc Announces Proposed Public Offering of 5 Million Ordinary Shares
Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering. JMP Securities is acting as the lead manager for the offering.
The Company intends to use the net proceeds from the offering for investment in commercial infrastructure for its two commercial products, Keveyis and Macrilen, continued development of its clinical-stage product candidates, Recorlev and veldoreotide, and for other general corporate purposes, which may include working capital, capital expenditures, acquisition of additional technologies or other forms of intellectual property, acquisition of assets or businesses that are complementary to its existing business, and general and administrative expenses.
A shelf registration statement relating to the ordinary shares was previously filed with the
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. Any offer, if at all, will be made only by means of the prospectus supplement and accompanying prospectus forming a part of the effective registration statement.
About
Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge's commercial portfolio within its rare neuromuscular and rare endocrine franchises includes Keveyis® (dichlorphenamide), the first and only
“Safe Harbor” Statement Under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements within the meaning of the federal securities laws. These statements involve risks and uncertainties that could cause actual results to differ materially, and relate to whether or not Strongbridge will be able to consummate the offering of ordinary shares described herein, including due to the satisfaction of customary closing conditions and prevailing market conditions, the anticipated use of the proceeds of the offering, which could change as a result of market conditions or for other reasons, and the impact of general economic, industry or political conditions in
Contacts:
Corporate and Media Relations
Elixir Health Public Relations
+1 862-596-1304
[email protected]
Investor Relations
U.S.:
Marcy Nanus
+1 646-378-2927
[email protected]
First House
Mitra Hagen Negård
+47 21 04 62 19
[email protected]
Suite 200
Tel. +1 610-254-9200
Fax. +1 215-355-7389
Source: Strongbridge Biopharma plc